Page 127 - 《中国药房》2024年7期

[10] WITKOWSKI M T.Modulation of CD19 surface expres‐ [23] CORDOBA S，ONUOHA S，THOMAS S，et al. CAR T
sion in B cell acute lymphoblastic leukemia[J]. Nat Immu‐ cells with dual targeting of CD19 and CD22 in pediatric
nol，2022，23：1410-1411. and young adult patients with relapsed or refractory B cell
[11] MILONE M C，XU J，CHEN S J，et al. Engineering en‐ acute lymphoblastic leukemia：a phase Ⅰ trial[J]. Nat
hanced CAR T-cells for improved cancer therapy[J]. Nat Med，2021，27（10）：1797-1805.
Cancer，2021，2（8）：780-793. [24] BOURNAZOS S，GUPTA A，RAVETCH J V. The role of
[12] PACENTA H L，LAETSCH T W，JOHN S. CD19 CAR T IgG Fc receptors in antibody-dependent enhancement[J].
cells for the treatment of pediatric pre-B cell acute lym‐ Nat Rev Immunol，2020，20（10）：633-643.
phoblastic leukemia[J]. Paediatr Drugs，2020，22（1）：1-11. [25] LOCATELLI F，ECKERT C，HRUSAK O，et al. Blinatu‐
[13] YANG J F，HE J P，ZHANG X，et al. Next-day manufac‐ momab overcomes poor prognostic impact of measurable
ture of a novel anti-CD19 CAR-T therapy for B-cell acute residual disease in pediatric high-risk first relapse B-cell
lymphoblastic leukemia：first-in-human clinical study[J]. precursor acute lymphoblastic leukemia[J]. Pediatr Blood
Blood Cancer J，2022，12（7）：104. Cancer，2022，69（8）：e29715.
[14] NOVARTIS. Novartis five-year Kymriah data show du‐ [26] BROWN P A，JI L Y，XU X X，et al. Effect of postrein‐
®
rable remission and long-term survival maintained in chil‐ duction therapy consolidation with blinatumomab vs. che‐
dren and young adults with advanced B-cell ALL[EB/OL]. motherapy on disease-free survival in children，adoles‐
（2022-06-12）[2024-03-15]. https：//finance.yahoo.com/ cents，and young adults with first relapse of B-cell acute
news/novartis-five-kymriah-data-show-093000684.html. lymphoblastic leukemia：a randomized clinical trial[J].
[15] KOKALAKI E，MA B，FERRARI M，et al. Dual targeting JAMA，2021，325（9）：833-842.
of CD19 and CD22 against B-ALL using a novel high- [27] ISSA G C，ALDOSS I，DIPERSIO J，et al. The menin in‐
sensitivity aCD22 CAR[J]. Mol Ther，2024，32（2）：556-558. hibitor revumenib in KMT2A-rearranged or NPM1-mu‐
[16] ZANETTI S R，VELASCO-HERNANDEZ T，GUTIERREZ- tant leukaemia[J]. Nature，2023，615（7954）：920-924.
AGÜERA F，et al. A novel and efficient tandem CD19- [28] WEN J Q，ZHOU M，SHEN Y L，et al. Poor treatment
and CD22-directed CAR for B cell ALL[J]. Mol Ther， responses were related to poor outcomes in pediatric B
2022，30（2）：550-563. cell acute lymphoblastic leukemia with KMT2A rearrange‐
[17] SHAH N N，HIGHFILL S L，SHALABI H，et al. CD4/ ments[J]. BMC Cancer，2022，22（1）：859.
CD8 T-cell selection affects chimeric antigen receptor [29] PIETERS R，LORENZO P D，ANCLIFFE P，et al. Out‐
（CAR） T-cell potency and toxicity：updated results from a come of infants younger than 1 year with acute lympho‐
phase Ⅰ anti-CD22 CAR T-cell trial[J]. J Clin Oncol， blastic leukemia treated with the interfant-06 protocol：re‐
2020，38（17）：1938-1950. sults from an international phase Ⅲ randomized study[J].
[18] FRY T J，SHAH N N，ORENTAS R J，et al. CD22-tar‐ J Clin Oncol，2019，37（25）：2246-2256.
geted CAR T cells induce remission in B-ALL that is [30] VAN DER SLUIS I M，LORENZO P D，KOTECHA R S，
naive or resistant to CD19-targeted CAR immunotherapy et al. Blinatumomab added to chemotherapy in infant lym‐
[J]. Nat Med，2018，24（1）：20-28. phoblastic leukemia[J]. N Engl J Med，2023，388（17）：
[19] COHEN A D，GARFALL A L，STADTMAUER E A，et al. 1572-1581.
B cell maturation antigen-specific CAR T cells are clini‐ [31] RUBINSTEIN J D，O’BRIEN M M. Inotuzumab ozo‐
cally active in multiple myeloma[J]. J Clin Invest，2019， gamicin in B-cell precursor acute lymphoblastic leukemia：
129（6）：2210-2221. efficacy，toxicity，and practical considerations[J]. Front
[20] HU Y X，ZHOU Y L，ZHANG M M，et al. CRISPR/Cas9- Immunol，2023，14：1237738.
engineered universal CD19/CD22 dual-targeted CAR-T [32] BRIVIO E，LOCATELLI F，LOPEZ-YURDA M，et al. A
cell therapy for relapsed/refractory B-cell acute lympho‐ phase Ⅰ study of inotuzumab ozogamicin in pediatric re‐
blastic leukemia[J]. Clin Cancer Res，2021，27（10）：2764- lapsed/refractory acute lymphoblastic leukemia （ITCC-
2772. 059 study）[J]. Blood，2021，137（12）：1582-1590.
[21] SHALABI H，QIN H Y，SU A，et al. CD19/22 CAR T [33] PENNESI E，MICHELS N，BRIVIO E，et al. Inotuzumab
cells in children and young adults with B-ALL：phase Ⅰ ozogamicin as single agent in pediatric patients with re‐
results and development of a novel bicistronic CAR[J]. lapsed and refractory acute lymphoblastic leukemia：re‐
Blood，2022，140（5）：451-463. sults from a phase Ⅱ trial[J]. Leukemia，2022，36（6）：
[22] SPIEGEL J Y，PATEL S，MUFFLY L，et al. CAR T cells 1516-1524.
with dual targeting of CD19 and CD22 in adult patients （收稿日期：2023-08-20 修回日期：2024-03-15）
with recurrent or refractory B cell malignancies：a phase 1 （编辑：胡晓霖）
trial[J]. Nat Med，2021，27（8）：1419-1431.

中国药房 2024年第35卷第7期 China Pharmacy 2024 Vol. 35 No. 7 · 889 ·